Research To Practice | Oncology Videos

Latest Episodes:

Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management Sep 21, 2025

Show notes

Featuring an interview with Dr Jonathan Strosberg, including the following topics:

Overview of extrapulmonary neuroendocrine carcinoma (NEC) (0:00)
Treatment strategies for extrapulmonary NEC (10:26)
Targeting DLL3 in extrapulmonary NEC (18:49)
Early clinical data with obrixtamig for extrapulmonary NEC (21:56)
Additional investigational agents for extrapulmonary NEC (25:44)
Case: A woman in her mid 50s with poorly differentiated metastatic NEC of unknown primary (27:20)
Case: A man in his early 60s with poorly differentiated metastatic esophageal NEC (32:30)
Clinical management of well-differentiated NEC (36:58)

CME information and select publications

Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy Sep 20, 2025

Show notes

Featuring an interview with Dr Beth Faiman, including the following topics:

Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00)
Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19)
Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00)
Patient eligibility to receive CAR T-cell therapy (13:23)
Differentiating among approved CAR T-cell therapies for MM (18:18)
Durability of responses to CAR T-cell therapy for MM (24:01)
Neurotoxicity with CAR T-cell therapies for MM (26:26)
Minimal residual disease monitoring in MM (29:39)
Support systems for the management of toxicities associated with CAR T-cell therapy (35:10)
Patients with MM experiencing durable responses to CAR T-cell therapy (43:11)

NCPD information and select publications

Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management (Companion Faculty Lecture) Sep 19, 2025

Show notes

Featuring a slide presentation and related discussion from Dr Jonathan Strosberg, including the following topics:

Overview of the classification, grading and incidence of neuroendocrine carcinoma (NEC) (0:00)
Overview of mutational profile, biomarker assessments and prognosis of NEC (3:45)
Current treatment paradigm for extrapulmonary NEC (8:59)
DLL3 as an emerging target biomarker in extrapulmonary NEC (17:46)
Novel therapeutic agents under investigation for extrapulmonary NEC (23:05)

CME information and select publications

Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy Sep 17, 2025

Show notes

Featuring perspectives from Dr Ana C Garrido-Castro and Prof Peter Schmid, including the following topics:

Introduction: Legendary Figures in Breast Cancer Research (0:00)
Case: A woman in her early 80s, a current smoker with a history of myocardial infarction and stroke, who develops recurrent triple-negative breast cancer (TNBC) — Justin Favaro, MD, PhD (6:44)
Case: A woman in her late 60s with metastatic TNBC and a PD-L1 level of 20% who receives chemotherapy/pembrolizumab followed by sacituzumab govitecan — Priya Rudolph, MD, PhD (25:08)
Case: A woman in her late 60s with localized TNBC who develops myocarditis while receiving neoadjuvant chemotherapy/pembrolizumab — Richard Zelkowitz, MD (33:53)
Case: A woman in her mid 60s with recurrent ER-negative, HER2-low, PI3K-mutant TNBC — Ranju Gupta, MD (37:49)
Case: A woman in her early 60s with recurrent TNBC confined to contralateral neck nodes — Eric H Lee, MD, PhD (42:10)
Case: A woman in her early 40s with metastatic TNBC who receives sacituzumab govitecan after multiple lines of chemotherapy — Estelamari Rodriguez, MD, MPH (48:10)
Case: A woman in her mid 70s with ER-negative, HER2-low breast cancer who develops an isolated brain metastasis — Dr Gupta (55:02)

CME information and select publications

Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management Sep 16, 2025

Show notes

Featuring an interview with Dr Neel Pasricha, including the following topics:

Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
Association of corneal toxicities with ADCs (4:56)
Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
Other ocular toxicities associated with cancer therapies (24:26)
Prevention and management of corneal toxicity (33:58)
Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)

CME information and select publications

Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management Sep 15, 2025

Show notes

Featuring perspectives from Prof Rebecca A Dent, Dr Hans Lee, Dr Neel Pasricha and Dr Tiffany A Richards, including the following topics:

Introduction: The Patient Experience (0:00)
Managing Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies — Dr Pasricha (10:28)
Ocular Toxicities in Multiple Myeloma (45:33)
Ocular Toxicities in Breast Cancer (50:34)

CME information and select publications

Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates Sep 12, 2025

Show notes

Featuring an interview with Dr Jacob Sands, including the following topics:

Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00)
- Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract
- Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623.
Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23)
- Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.
Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12)
- Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract
- Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501.
- Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521.
Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11)
- Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract

CME information and select publications

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1 Sep 08, 2025

Show notes

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics:

Introduction: ER-Positive Metastatic Breast Cancer — Bringing Research Data into Practice (0:00)
Key Issues from the General Medical Oncologists (GMO) Survey (3:43)
Faculty Cases and GMO Questions (44:43)

CME information and select publications

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise Gleason on Optimizing Patient Care Sep 06, 2025

Show notes

Featuring an interview with Ms Charise Gleason, including the following topics:

Progress and change in the management of multiple myeloma (MM) (0:00)
Patient- and disease-specific factors guiding therapeutic decision-making for newly diagnosed MM (5:11)
Role of anti-CD38 antibodies in the management of MM (12:14)
Emerging treatment options for smoldering myeloma (23:08)
Optimizing long-term outcomes for patients with MM (25:38)
Tailoring therapy for older adults and patients with preexisting comorbidities (29:59)
Case: A woman in her early 80s with newly diagnosed transplant-ineligible MM who experienced a complete response with first-line daratumumab/lenalidomide and low-dose dexamethasone (34:34)
Case: A man in his early 60s with progressive back pain from standard-risk MM who experienced a complete response with daratumumab with lenalidomide/bortezomib/dexamethasone (42:05)
Building therapeutic relationships and integrating holistic care in oncology practice (47:13)

NCPD information and select publications

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu Sep 05, 2025

Show notes

Featuring an interview with Prof Xavier Leleu including the following topics:

Introduction: Historical treatment advances in multiple myeloma (MM) (0:00)
Contemporary treatment for patients with newly diagnosed MM who are eligible for transplant (13:18)
Prognosis and life expectancy for patients with MM (19:39)
Mechanistic differences among anti-CD38 monoclonal antibodies (27:05)
Routes of administration of anti-CD38 monoclonal antibodies (30:21)
Background and treatment of smoldering myeloma (41:05)
Treatment for older patients with newly diagnosed MM who are not eligible for transplant (46:41)

NCPD information and select publications